Iron Deposition in Subcortical Nuclei of Parkinson’s Disease: A Meta-Analysis of Quantitative Iron-Sensitive Magnetic Resonance Imaging Studies

Iron Deposition in Subcortical Nuclei of Parkinson’s Disease: A Meta-Analysis of Quantitative Iron-Sensitive Magnetic Resonance Imaging Studies

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. Among the various pathological mechanisms implicated in PD, iron deposition in the brain has gained significant attention due to its role in oxidative stress, cellular damage, and neurodegeneration. Quantitative iron-sensitive magnetic resonance imaging (MRI) techniques, such as R2* mapping and quantitative susceptibility mapping (QSM), have emerged as powerful tools to non-invasively assess iron content in the brain. This meta-analysis aims to comprehensively evaluate the patterns of iron deposition in subcortical nuclei of PD patients compared to healthy controls (HCs) and patients with atypical parkinsonian syndromes (APSs), including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). The study also explores the diagnostic performance of iron-sensitive MRI in differentiating PD from these conditions.

Background and Significance

Iron is essential for various physiological processes in the brain, including neurotransmitter synthesis and myelin production. However, excessive iron accumulation can lead to oxidative stress, lipid peroxidation, and neuronal death, which are key contributors to neurodegenerative diseases like PD. Postmortem studies have consistently shown elevated iron levels in the substantia nigra (SN), putamen (PUT), globus pallidus (GP), and red nucleus (RN) of PD patients. These findings have spurred interest in using MRI to quantify iron deposition in vivo, as it could provide valuable insights into disease progression and aid in differential diagnosis.

Iron-sensitive MRI techniques, such as R2 mapping and QSM, have been widely used to estimate iron content in the brain. R2 mapping measures the transverse relaxation rate, which is influenced by iron-induced magnetic field inhomogeneities. QSM, on the other hand, quantifies local magnetic susceptibility variations, providing a more direct measure of iron concentration. Despite the growing body of literature on this topic, there is significant heterogeneity in the reported patterns of iron deposition in PD, necessitating a comprehensive meta-analysis to synthesize the available evidence.

Methods

This meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic literature search was conducted using PubMed, Embase, and Web of Science databases to identify studies investigating iron content in PD patients using R2* and QSM techniques. The search included studies published up to May 1, 2023. The quality of case-control and cohort studies was assessed using the Newcastle-Ottawa Scale, while diagnostic studies were evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) criteria.

Data extraction focused on study characteristics, subject demographics, MRI technical details, and quantitative outcomes of iron content in various brain regions. The regions of interest (ROIs) included the SN, SN pars compacta (SNpc), SN pars reticulata (SNr), RN, PUT, GP, caudate nucleus (CN), thalamus (TH), subthalamic nucleus (STN), and dentate nucleus (DN). Standardized mean differences (SMDs) were calculated to compare iron content between PD patients and HCs or APS patients. Subgroup analyses were performed based on the MRI sequence (R2* vs. QSM), and meta-regression was conducted to assess the influence of age, disease duration, Hoehn and Yahr (H-Y) stage, and Unified Parkinson’s Disease Rating Scale III (MDS-UPDRS III) scores on iron content.

Results

A total of 77 studies involving 3192 PD patients, 209 MSA patients, 174 PSP patients, and 2447 HCs were included in the meta-analysis. The results revealed elevated iron content in several subcortical nuclei of PD patients compared to HCs, including the SNr, SNpc, SN, RN, GP, PUT, and TH. Specifically, the SNr showed the highest SMD (1.541), followed by the SNpc (1.517) and SN (0.909). No significant differences were observed in the CN, DN, and STN.

Subgroup analysis based on MRI sequence indicated that QSM was more sensitive than R2 in detecting increased iron content in the SNr, SNpc, SN, GP, RN, PUT, and TH. R2 mapping also showed elevated iron content in the SNr, SNpc, and SN, but not in the other regions. Meta-regression analysis revealed a positive correlation between iron content in the SN and MDS-UPDRS III scores, as well as between iron content in the RN and H-Y stage, suggesting that iron deposition in these regions may be associated with disease severity.

In comparison to MSA patients, PD patients exhibited lower iron content in the PUT, RN, SN, and CN. Similarly, PD patients had lower iron content in the PUT, RN, GP, SN, and CN compared to PSP patients. These findings highlight distinct patterns of iron deposition that could aid in the differential diagnosis of PD and APSs.

Diagnostic Performance

The diagnostic performance of iron-sensitive MRI was evaluated using summary receiver operating characteristic (SROC) curves. The highest diagnostic accuracy for distinguishing PD from HCs was observed in the SN (AUC: 0.85), with pooled sensitivity and specificity of 0.788 and 0.788, respectively. For differentiating PD from MSA, the PUT showed the highest AUC (0.90), with sensitivity and specificity of 0.630 and 0.918, respectively. The RN demonstrated the best diagnostic performance in distinguishing PD from PSP (AUC: 0.86), with sensitivity and specificity of 0.884 and 0.796, respectively.

Discussion

This meta-analysis provides robust evidence that quantitative iron-sensitive MRI can effectively detect iron deposition in subcortical nuclei of PD patients. The elevated iron content in the SN, SNpc, SNr, RN, GP, PUT, and TH aligns with postmortem findings and underscores the role of iron in PD pathogenesis. The positive correlation between iron content and disease severity further supports the potential of iron-sensitive MRI as a biomarker for PD progression.

The distinct patterns of iron deposition in PD compared to MSA and PSP patients suggest that iron-sensitive MRI could be a valuable tool for differential diagnosis. However, the diagnostic accuracy of single nuclei may be insufficient, highlighting the need for multimodal MRI approaches to improve diagnostic and differential diagnostic efficiencies.

Several limitations should be acknowledged. Most included studies were cross-sectional, limiting the ability to establish causal relationships between iron deposition and PD progression. Additionally, the lack of pathological data on iron deposition in the included studies precludes a direct correlation between imaging findings and iron pathology. Future longitudinal studies with larger sample sizes and pathological validation are needed to further elucidate the spatiotemporal distribution of iron deposition in PD.

Conclusion

This meta-analysis demonstrates that quantitative iron-sensitive MRI is a feasible technique for assessing iron content in subcortical nuclei of PD patients. The distinct patterns of iron deposition in PD compared to HCs and APS patients provide valuable insights into disease mechanisms and potential diagnostic markers. However, the iron deposition of single nuclei may not be sufficient to accurately diagnose PD, necessitating the integration of multimodal MRI techniques. Future research should focus on longitudinal studies and the development of advanced imaging biomarkers to enhance the diagnostic and differential diagnostic capabilities of PD.

doi.org/10.1097/CM9.0000000000003167

Was this helpful?

YesNo

0 / 0